Bactericidal activity in sputum according to treatment arm as assessed by colony counts (left) and time to positivity in automated liquid culture (MGIT TTP, right).

<p>Lines indicate prediction and shading 90% confidence interval (CI) as determined by mixed effects model repeated measures analysis, using day as a categorical variable. The vertical axis of the right hand figure is inverted to facilitate visual comparison with CFU findings. At 14 days, the 90% CI of all treatments excluded zero.</p

Distributions of minimal inhibitory concentrations (MICs) to sutezolid (PNU-100480) pre and post treatment (rows and columns, respectively), according to dosing schedule.

<p>Values in each cell indicate numbers of patients. Cells shaded red are those in which MIC values increased, whereas they decreased in those shaded blue. No change was apparent in MIC values of the metabolite (PNU-101603, not shown).</p

Geometric mean pharmacokinetic parameters in patients of sutezolid and its major metabolite following dosing for 14 Days.

<p>CV = coefficient of variation.</p

Plasma concentrations of sutezolid (pink) and its major metabolite (yellow) at steady state (day 13–14) in patients treated with sutezolid 600 mg BID (left) or 1200 mg QD (right).

<p>Solid lines indicate medians; shading indicates 90% CI. Lower and upper dotted lines indicate median pre-treatment MIC values for parent and metabolite, respectively.</p

Treatment-emergent ALT increases in sutezolid-treated subjects.

<p>Treatment-emergent ALT increases in sutezolid-treated subjects.</p